Active Filter(s):
Details:
Under the divestiture, AUG gains rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose). AVTX-801 is a therapeutic dose of D-galactose currently in development for the treatment of phosphoglucomutase 1 deficiency.
Lead Product(s): Alpha-D-Galactose
Therapeutic Area: Genetic Disease Product Name: AVTX-801
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: AUG Therapeutics
Deal Size: $45.1 million Upfront Cash: $0.1 million
Deal Type: Divestment September 12, 2023
Details:
This trial will study the safety, tolerability, and efficacy of CERC-801 in patients with PGM1-CDG using daily therapeutic doses of CERC-801 in approximately ten patients.
Lead Product(s): Alpha-D-Galactose
Therapeutic Area: Genetic Disease Product Name: CERC-801
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Cerecor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 17, 2020